Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment-Reference-Cited by-同舟云学术

Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment

Published:2013-02 Issue:2 Volume:226 Page:459-465
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Kwakernaak Arjan J.,Lambert Gilles,Slagman Maartje C.J.,Waanders Femke,Laverman Gozewijn D.,Petrides Francine,Dikkeschei Bert D.,Navis Gerjan,Dullaart Robin P.F.

Funder

Novartis

Heart Research Foundation of Australia

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome;Joven;N Engl J Med,1990

2. Role of elevated lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients;Dullaart;Kidney Int,1993

3. Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin;Krikken;Expert Opin Ther Targets,2009

4. Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment;Vogt;Nephrol Dial Transplant,2006

5. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein;Kappelle;J Intern Med,2011

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proprotein convertase subtilisin/kexin type 9 targets megalin in the kidney proximal tubule and aggravates proteinuria in nephrotic syndrome;Kidney International;2023-10

2. Targeting PCSK9 to tackle cardiovascular disease;Pharmacology & Therapeutics;2023-09

3. PCSK9 in extrahepatic tissues: What can we expect from its inhibition?;European Atherosclerosis Journal;2023-08-31

4. Pleiotropy of PCSK9: Functions in Extrahepatic Tissues;Current Cardiology Reports;2023-07-10

5. Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus;Renal Failure;2023-05-29